Skip to main content
Erschienen in: European Journal of Pediatrics 2/2008

01.02.2008 | Original Paper

Abnormalities in the hair morphology of patients with some but not all types of mucopolysaccharidoses

verfasst von: Marcelina Malinowska, Joanna Jakóbkiewicz-Banecka, Anna Kloska, Anna Tylki-Szymańska, Barbara Czartoryska, Ewa Piotrowska, Alicja Węgrzyn, Grzegorz Węgrzyn

Erschienen in: European Journal of Pediatrics | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

Mucopolysaccharidoses (MPS) are a group of inherited, progressive, metabolic diseases, caused by the deficiency of one of the enzymes involved in the degradation of glycosaminoglycans (GAGs). The disease is usually fatal, with the life span of most untreated MPS patients being between one and two decades. In this report, on the basis of scanning electron microscopy (SEM) studies, we demonstrate that, besides the many other symptoms of MPS, there are characteristic abnormalities in the hair morphology of patients suffering from some types of this disease (MPS I, MPS II, MPS IIIA, MPS IIIB), but not from other types (MPS IVA, MPS IVB, MPS VI), where the changes are minor, if any. Different GAGs accumulate in the tissues of patients suffering from the various MPS types, and analysis of the disease types in which severe hair abnormalities occur or not could suggest that the accumulation of heparan sulfate, rather than dermatan sulfate or keratan sufate, may be responsible for the major changes in hair morphology. Considerable abnormalities in hair morphology occur in patients suffering from MPS I, MPS II, MPS IIIA, and MPS IIIB, but not in patients suffering from MPS IVA, MPS IVB, and MPS VI; this feature might potentially be used as an additional test for the assessment of the efficacy of treatments for MPS patients (types I, II, IIIA, and IIIB).
Literatur
1.
Zurück zum Zitat Bosch A, Heard JM (2003) Gene therapy for mucopolysaccharidosis. Int Rev Neurobiol 55:271–296PubMedCrossRef Bosch A, Heard JM (2003) Gene therapy for mucopolysaccharidosis. Int Rev Neurobiol 55:271–296PubMedCrossRef
2.
3.
Zurück zum Zitat Brooks DA, Muller VJ, Hopwood JJ (2006) Stop-codon read-through for patients affected by a lysosomal storage disorder. Trends Mol Med 12(8):367–373PubMedCrossRef Brooks DA, Muller VJ, Hopwood JJ (2006) Stop-codon read-through for patients affected by a lysosomal storage disorder. Trends Mol Med 12(8):367–373PubMedCrossRef
4.
Zurück zum Zitat Charan RK, Nauer G, Wagner U, Klabuschnig A, Lubec G (1986) Physicochemical hair conformation of patients with Sanfilippo disease type IIIA. Padiatr Padol 21(3):249–256PubMed Charan RK, Nauer G, Wagner U, Klabuschnig A, Lubec G (1986) Physicochemical hair conformation of patients with Sanfilippo disease type IIIA. Padiatr Padol 21(3):249–256PubMed
5.
Zurück zum Zitat Crump IA, Danks DM (1971) Simple method for cutting transverse sections of hair. Comments on shape of hair in Hurler and Sanfilippo syndromes. Arch Dis Child 46(247):383–386PubMedCrossRef Crump IA, Danks DM (1971) Simple method for cutting transverse sections of hair. Comments on shape of hair in Hurler and Sanfilippo syndromes. Arch Dis Child 46(247):383–386PubMedCrossRef
6.
Zurück zum Zitat Ellinwood NM, Vite CH, Haskins ME (2004) Gene therapy for lysosomal storage diseases: the lessons and promise of animal models. J Gene Med 6(5):481–506PubMedCrossRef Ellinwood NM, Vite CH, Haskins ME (2004) Gene therapy for lysosomal storage diseases: the lessons and promise of animal models. J Gene Med 6(5):481–506PubMedCrossRef
7.
Zurück zum Zitat Harmatz P, Giugliani R, Schwartz I, Guffon N, Teles EL, Miranda MC, Wraith JE, Beck M, Arash L, Scarpa M, Yu ZF, Wittes J, Berger KI, Newman MS, Lowe AM, Kakkis E, Swiedler SJ; MPS VI Phase 3 Study Group (2006) Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr 148(4):533–539PubMedCrossRef Harmatz P, Giugliani R, Schwartz I, Guffon N, Teles EL, Miranda MC, Wraith JE, Beck M, Arash L, Scarpa M, Yu ZF, Wittes J, Berger KI, Newman MS, Lowe AM, Kakkis E, Swiedler SJ; MPS VI Phase 3 Study Group (2006) Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr 148(4):533–539PubMedCrossRef
8.
Zurück zum Zitat Hinek A, Wilson SE (2000) Impaired elastogenesis in Hurler disease: dermatan sulfate accumulation linked to deficiency in elastin-binding protein and elastic fiber assembly. Am J Pathol 156(3):925–938PubMed Hinek A, Wilson SE (2000) Impaired elastogenesis in Hurler disease: dermatan sulfate accumulation linked to deficiency in elastin-binding protein and elastic fiber assembly. Am J Pathol 156(3):925–938PubMed
9.
Zurück zum Zitat Kloska A, Bohdanowicz J, Konopa G, Tylki-Szymańska A, Jakóbkiewicz-Banecka J, Czartoryska B, Liberek A, Węgrzyn A, Węgrzyn G (2005) Changes in hair morphology of mucopolysaccharidosis I patients treated with recombinant human alpha-L-iduronidase (laronidase, Aldurazyme). Am J Med Genet A 139(3):199–203PubMed Kloska A, Bohdanowicz J, Konopa G, Tylki-Szymańska A, Jakóbkiewicz-Banecka J, Czartoryska B, Liberek A, Węgrzyn A, Węgrzyn G (2005) Changes in hair morphology of mucopolysaccharidosis I patients treated with recombinant human alpha-L-iduronidase (laronidase, Aldurazyme). Am J Med Genet A 139(3):199–203PubMed
10.
Zurück zum Zitat Lubec G, Nauer G (1988) Infrared spectroscopy studies on the conformation of human hair. Padiatr Padol 23(2):101–108PubMed Lubec G, Nauer G (1988) Infrared spectroscopy studies on the conformation of human hair. Padiatr Padol 23(2):101–108PubMed
11.
Zurück zum Zitat Muenzer J, Wraith JE, Beck M, Giugliani R, Harmatz P, Eng CM, Vellodi A, Martin R, Ramaswami U, Gucsavas-Calikoglu M, Vijayaraghavan S, Wendt S, Puga A, Ulbrich B, Shinawi M, Cleary M, Piper D, Conway AM, Kimura A (2006) A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 8(8):465–473PubMedCrossRef Muenzer J, Wraith JE, Beck M, Giugliani R, Harmatz P, Eng CM, Vellodi A, Martin R, Ramaswami U, Gucsavas-Calikoglu M, Vijayaraghavan S, Wendt S, Puga A, Ulbrich B, Shinawi M, Cleary M, Piper D, Conway AM, Kimura A (2006) A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 8(8):465–473PubMedCrossRef
12.
Zurück zum Zitat Neufeld EF, Muenzer J (2001) The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, 8th edn. McGraw-Hill, New York, pp 3421–3452 Neufeld EF, Muenzer J (2001) The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, 8th edn. McGraw-Hill, New York, pp 3421–3452
13.
Zurück zum Zitat Piotrowska E, Jakóbkiewicz-Banecka J, Barańska S, Tylki-Szymańska A, Czartoryska B, Węgrzyn A, Węgrzyn G (2006) Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses. Eur J Hum Genet 14(7):846–852PubMedCrossRef Piotrowska E, Jakóbkiewicz-Banecka J, Barańska S, Tylki-Szymańska A, Czartoryska B, Węgrzyn A, Węgrzyn G (2006) Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses. Eur J Hum Genet 14(7):846–852PubMedCrossRef
14.
Zurück zum Zitat Roberts AL, Thomas BJ, Wilkinson AS, Fletcher JM, Byers S (2006) Inhibition of glycosaminoglycan synthesis using rhodamine B in a mouse model of mucopolysaccharidosis type IIIA. Pediatr Res 60(3):309–314PubMedCrossRef Roberts AL, Thomas BJ, Wilkinson AS, Fletcher JM, Byers S (2006) Inhibition of glycosaminoglycan synthesis using rhodamine B in a mouse model of mucopolysaccharidosis type IIIA. Pediatr Res 60(3):309–314PubMedCrossRef
15.
Zurück zum Zitat Schiffmann R, Brady RO (2002) New prospects for the treatment of lysosomal storage diseases. Drugs 62(5):733–742PubMedCrossRef Schiffmann R, Brady RO (2002) New prospects for the treatment of lysosomal storage diseases. Drugs 62(5):733–742PubMedCrossRef
16.
Zurück zum Zitat Silengo M, Valenzise M, Sorasio L, Ferrero GB (2002) Hair as a diagnostic tool in dysmorphology. Clin Genet 62(4):270–272PubMedCrossRef Silengo M, Valenzise M, Sorasio L, Ferrero GB (2002) Hair as a diagnostic tool in dysmorphology. Clin Genet 62(4):270–272PubMedCrossRef
18.
Zurück zum Zitat Teschler-Nicola M, Killian W (1982) Observations on hair shaft morphology in mucopolysaccharidoses. J Ment Defic Res 26(Pt 3):193–202PubMed Teschler-Nicola M, Killian W (1982) Observations on hair shaft morphology in mucopolysaccharidoses. J Ment Defic Res 26(Pt 3):193–202PubMed
19.
Zurück zum Zitat Wraith JE, Clarke LA, Beck M, Kolodny EH, Pastores GM, Muenzer J, Rapoport DM, Berger KI, Swiedler SJ, Kakkis ED, Braakman T, Chadbourne E, Walton-Bowen K, Cox GF (2004) Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr 144(5):581–588PubMedCrossRef Wraith JE, Clarke LA, Beck M, Kolodny EH, Pastores GM, Muenzer J, Rapoport DM, Berger KI, Swiedler SJ, Kakkis ED, Braakman T, Chadbourne E, Walton-Bowen K, Cox GF (2004) Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr 144(5):581–588PubMedCrossRef
Metadaten
Titel
Abnormalities in the hair morphology of patients with some but not all types of mucopolysaccharidoses
verfasst von
Marcelina Malinowska
Joanna Jakóbkiewicz-Banecka
Anna Kloska
Anna Tylki-Szymańska
Barbara Czartoryska
Ewa Piotrowska
Alicja Węgrzyn
Grzegorz Węgrzyn
Publikationsdatum
01.02.2008
Verlag
Springer-Verlag
Erschienen in
European Journal of Pediatrics / Ausgabe 2/2008
Print ISSN: 0340-6199
Elektronische ISSN: 1432-1076
DOI
https://doi.org/10.1007/s00431-007-0462-7

Weitere Artikel der Ausgabe 2/2008

European Journal of Pediatrics 2/2008 Zur Ausgabe

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.